Regofinil API

Name	Regofinil
Chinese name	瑞戈非尼
Cas Number	755037-03-7
Source	India
Qualifications	USDMF/-/-/-/-

Regorafenib is a new type of oral multikinase inhibitor. It is a new generation of oral multi-target tyrosine kinase inhibitor developed by BAYER after Sorafenib. It was approved by the FDA for the treatment of gastrointestinal tract in 2013. Mass tumor. The original research was approved for listing in China in 2017. The drug has been approved for use in more than 90 countries and regions including the United States, the European Union, and Japan. In addition to inhibiting the KIT and PDGFRA kinase targets, regorafenib can also act on RET, BRAF, RAF1, VEGFR, FGFR, PDGFRP and other targets. The Phase II study of regafini for advanced GIST that failed imatinib or sunitinib treatment showed good results, with a clinical benefit rate (complete remission, partial remission, stable disease ≥16 weeks) of 79%, The median PFS was 10 months. Compared with other monoclonal antibody targeted therapy drugs for colorectal cancer, the small molecular structure of regorafenib can enter the cell membrane to exert anti-tumor effects. The activity characteristics of regorafenib are significantly different from other multikinase inhibitors including sorafenib, axitinib, etc., which is reflected in a more comprehensive target. The listing of regorafenib has brought significantly improved clinical survival benefits to patients.

Hot Tags: regofinil api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Tippyridine Hydrochloride API, Ranolazine API, Salmeterol Xinafoate API, Temozolomide API, Bemeprost API, Deoxycholic Acid API

• Previous: Azelastine Hydrochloride API
• Next: Methylprednisolone API